The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award!JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) --…
- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant…
New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with Disopyramideand Longer-Term Effect on…
The Annual Meeting is the foremost educational and scientific event for gynecologic oncologistsStenoparib has shown clinical benefit in…
Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the…
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and…
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved,…
Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry…
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα…
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients…